Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma

NCT03528408 is registered in ClinicalTrials.gov with Suthee Rapisuwon as lead sponsor.

NCT NCT03528408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03528408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Lead sponsor
Suthee Rapisuwon
Phase
Phase 2
Overall status
Unknown status
Start date
July 26, 2018
Completion date
June 30, 2023
Enrollment
52 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, ocular melanoma